Novo Nordisk has become a household name thanks to Wegovy and Ozempic. What are the risks that stem from that attention, and just how significant is the long-term opportunity? In the first of a series of Digging Deeper conversations, Investment Manager Lindsay Scott shares her thoughts on the obesity and diabetes markets.
22 minute watch
ARE YOU AN INSTITUTIONAL INVESTOR?
The information in this area of the website is intended for use by Institutional Investors and Consultants only. It is not intended for use by other investors including members of the general public.
By clicking “Yes” you hereby acknowledge, agree and represent to Walter Scott & Partners Limited that you are an Institutional Investor/Consultant and that you have read and understood the Terms and Conditions which apply.
The information contained on this page is not appropriate for, and should not be used or relied upon by, Retail Investors.
By clicking “No” you will be redirected to our Homepage.
Walter Scott & Partners Limited offers a variety of services intended solely for Institutional Clients from certain countries or regions. We do not offer these services outside of these intended countries or regions. Your country of legal residence will determine the services available to you. The information provided does not constitute an offer of or solicitation for purchase or sale of securities or provision of any investment services.
